Hong Kong Baptist University

4月29日，上海实业 (集团) 有限公司（以下简称“上实集团”）与香港浸会大学（以下简称“浸大”）签署战略合作协议，双方将结合优势，共同推动香港第三家医学院的创立，服务香港发展成为国际医疗培训、研究和创新枢纽。浸大校长卫炳江教授表示，浸大为亚洲最优秀的高等教育学府之一，在生物医学、中医药及计算机科学等领域具有深厚的科研基础，多个药物研发项目获得美国食品和药物管理局的临床试验批准或孤儿药资格。希望与上实集团及旗下上海医药围绕支持新医学院的建立，生物医药研究与创新、大湾区医疗融合等领域展开合作，共同推动前沿医学研究。上实集团副总裁、上海医药董事长杨秋华代表上实集团出席签约仪式。他表示，上实集团是一家立足香港、依托上海，服务国家战略的国际化企业集团，正聚焦生命健康、环境健康产业主赛道，积极打造“产学研医资保”协同创新的生物医药生态圈。上海医药是上实集团布局生命健康产业的核心平台，具有“工商研投”全产业链优势。上实集团、上海医药致力于通过研发创新赋能生物医药产业的转型升级，期待双方合作为香港及大湾区的医疗教育、中药材溯源、中医药传承创新和国际化发展注入新动力，助力国家医药医疗体系发展。 上海医药执行董事、总裁沈波，浸大新医学院筹备委员会联席主席李心平教授、新医学院筹备委员会联席主席及前沿转化医学研究院联合创始人霍文逊教授，以及双方相关部门、学院负责人等参加。来源：【上实集团】微信公众号

点击蓝字  关注我们 2025年1月3日，长春金赛药业有限责任公司（以下简称“金赛药业”）与北京东方运嘉药业有限公司（以下简称“东方运嘉”）战略合作的中药1.1类创新药——小儿黄金止咳颗粒（商标名：金赛克®）获国家药品监督管理局（以下简称“NMPA”）批准上市，适用于3至7岁儿童急性咳嗽痰热阻肺证，为儿童急性支气管炎咳嗽临床诊治提供了更优方案。 组方经典，循证充分 小儿黄金止咳颗粒（金赛克®）源自国医大师晁恩祥教授的临床经验方，经过全国知名老中医团队的多轮处方优化，组方精简、配伍相宜，包含黄芩、金荞麦、蜜枇杷叶、浙贝母、虎杖和甘草，具有清肺化痰、肃肺止咳之效。 历经“十年磨一剑”的研发，该药品积累了超过500例患儿的应用经验，并成功完成Ⅱ、Ⅲ期临床试验，于2024年2月被国家药监局药品审评中心纳入“优先审评品种”。 晁恩祥教授 国医大师  首都国医名师 中日友好医院博士生及博士后导师 中医内科首席专家 香港浸会大学荣誉教授 国家 中医肺病和急诊学科带头人 守正创新，疗效确切 小儿黄金止咳颗粒（金赛克®）Ⅲ期临床试验由首都医科大学附属北京儿童医院徐保平教授牵头，由全国21家中心参与，共同完成。 随机、双盲、安慰剂平行对照的多中心Ⅲ期临床试验显示，小儿黄金止咳颗粒（金赛克®）可显著改善日间咳嗽和夜间咳嗽症状，降低咳嗽严重程度，其治疗7天咳嗽消失率达74%，中医证候疗效有效率达93.5%。 安全性良好， 槐花口感便于儿童用药 小儿黄金止咳颗粒（金赛克®）的安全性良好，不含石膏、麻黄等大寒成瘾性药材，加上其独特的槐花口感，更适合儿童用药。 徐保平教授寄语 “守正，创新！作为小儿黄金止咳颗粒三期研究主PI，见证了中医药临床循证的高质量发展。传承经典组方，使用科学证据，相信一定能为广大儿童急性咳嗽患者带来新的临床解决方案。” 徐保平教授 医学博士，主任医师 教授，博士生导师 首都医科大学附属北京儿童医院呼吸中心办公室主任 国家呼吸系统疾病临床医学研究中心副主任 中华医学会儿科学分会呼吸学组组长、疑难少见病协作组组长 中国中药协会儿童健康与研究专业委员会副主任委员、呼吸学组组长 优势互补， 为儿童健康成长“保驾护航” 金赛药业始终聚焦妇儿健康，其中儿科作为核心业务，多年来金赛药业关注临床需求，从儿童生长迟缓和性发育异常出发，全面布局包括儿童呼吸、儿童神经、儿童肥胖、儿童营养、儿童足脊健康等多个领域，以期提供“儿童成长全过程”的产品与服务。 金赛药业呼吸业务负责人表示，金赛药业与东方运嘉就小儿黄金止咳颗粒（金赛克®）达成相关权益合作，共同推进商业化进程，是公司在儿科呼吸领域的重要布局。未来金赛药业呼吸及综合药品事业部将以儿童呼吸健康领域为核心，聚焦呼吸感染、过敏免疫等疾病，实现诊疗一体化布局，以卓越创新的产品和前沿治疗方案服务临床、造福患儿。 金赛药业 百年成长

HONG KONG, Dec. 23, 2024 /PRNewswire/ -- A research led by Hong Kong Baptist University (HKBU) and the Shanghai Sixth People's Hospital Affiliated to School of Medicine at Shanghai Jiao Tong University (Shanghai Sixth People's Hospital) has discovered that an aptamer developed by HKBU can be used to treat X-linked hypophosphatemia (XLH), a rare bone disease. The aptamer, originally developed to treat osteogenesis imperfecta, has been granted Orphan Drug Designation and Pediatric Rare Disease Designation by the U.S. Food and Drug Administration (FDA). Continue Reading Professor Zhang Ge, Associate Dean (Research) of Chinese Medicine and Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU, in collaboration with other institutions, has developed an aptamer for the treatment of X-linked hypophosphatemia, which has been granted Orphan Drug Designation and Pediatric Rare Disease Designation by the U.S. FDA. XLH ("X" denotes X-chromosome, a sex-determining chromosome) is a rare bone disease characterised by hypophosphatemia (i.e., low phosphate in blood). It is caused by a mutation in the phosphate regulating endopeptidase homolog X-linked (PHEX) gene, and its inheritance pattern follows an X-linked dominant mode. The bone tissue of XLH patients cannot mineralise properly, thereby affecting the hardness of the bones. The cartilage between the ribs of children with XLH grows and connects like beads strung together. They also result in limb deformities and growth retardation. Adult patients experience symptoms such as osteomalacia, bone pain, changes in body shape, shorter stature and pseudo-fractures, leading to reduced mobility or even disability. Professor Zhang Ge, Associate Dean (Research) of Chinese Medicine and Director of the Law Sau Fai Institute for Advancing Translational Medicine in Bone and Joint Diseases at HKBU, and Professor Zhang Zhenlin, Director of Osteoporosis and Bone Diseases of the Shanghai Sixth People's Hospital, along with Aptacure Therapeutics Ltd., have developed a long-acting sclerostin-loop3 oligonucleotide aptamer for the treatment of XLH. This aptamer has been granted Orphan Drug Designation and Pediatric Rare Disease Designation by the U.S. FDA for treatment of XLH earlier this year. Researchers conducted serum tests on 51 patients with XLH from the Shanghai Sixth People's Hospital. The results showed that their serum sclerostin levels were approximately 4.5 times higher than those of healthy individuals of the same age and gender. Sclerostin is a protein that inhibits bone growth while playing a protective role in the cardiovascular system. Genetic evidence shows that sclerostin deficiency significantly elevates serum phosphorus levels and increases bone mass in mice. However, the monoclonal sclerostin antibody currently used increases the risk of heart attacks, stroke and cardiovascular diseases. The research team discovered that sclerostin inhibits bone formation and protects the cardiovascular system through different domains of the protein. When sclerostin loses the "loop3 domain", bone mass and strength increase, but its cardiovascular protective effect remains unaffected. The "loop3 domain" of sclerostin can therefore serve as a therapeutic molecular target to promote bone formation, with no safety concern in the cardiovascular system. The researchers then screen out oligonucleotide aptamers Apc001 that can inhibit the sclerostin loop3. Animal experiments showed that Apc001 can promote bone formation without increasing cardiovascular risk. It can also significantly increase the blood phosphorus levels of mice with XLH. This is expected to provide a drug candidate for the precise treatment of XLH patients. According to the regulations of the U.S. FDA, once a drug under development obtains Orphan Drug Designation, its subsequent research and development may allow for a reduction in the number of clinical trial samples, be exempt from new drug marketing authorisation fees, and enjoy seven years of market exclusivity. Pediatric Rare Disease Designation allows drugs to be reviewed with priority. Having been designated as both an orphan drug and a pediatric rare disease by the U.S. FDA, Apc001 can accelerate its clinical translation and is expected to benefit patients with XLH sooner. Currently, the pilot scale production of Apc001 has been completed and is undergoing the preclinical toxicological assessment by a third party. Apc001 is scheduled to enter clinical trials in both Mainland China and the U.S. SOURCE Hong Kong Baptist University WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED